Monthly Archives: November 2020

Colleagues, I hope you were able to enjoy the Thanksgiving holiday and had an opportunity for some rest. As I have commented before, we are in a marathon and not a sprint when it comes to our pandemic response. There is a genuine need for self-care as … Continue reading →

The commensal microbiota has been implicated in the regulation of a diverse array of physiological processes, both within the gastrointestinal tract and at distant tissue sites. Cancer is no exception, and distinct aspects of the microbiota have been r… Continue reading →

Chronic liver disease is reaching epidemic proportions with the increasing prevalence of obesity, non-alcoholic liver disease, and alcohol overuse worldwide. Most patients with are not candidates for liver transplantation, even if they have end-stage l… Continue reading →

There have been numerous human studies reporting associations between the intestinal microbiome and functional gastrointestinal disorders (FGIDs), and independently animal studies have explored microbiome-driven mechanisms underlying FGIDs. However, th… Continue reading →

Changes in the intestinal microbiome have been associated with obesity and type 2 diabetes, in epidemiological studies and studies of the effects of fecal transfer in germ-free mice. We review the mechanisms by which alterations in the intestinal micro… Continue reading →

Inflammatory bowel diseases (IBD) develop via convergence of environmental, microbial, immunological, and genetic factors. Alterations in the gut microbiota have been associated with development and progression of IBD, but it is not clear which populat… Continue reading →

Use of microbiome-based biomarkers in diagnosis, prognosis, risk profiling, and precision therapy requires definition of a healthy microbiome in different populations. To determine features of the intestinal microbiota associated with health, however, … Continue reading →